Skip to main content

Table 4 Provisional data on CMV seropositivity in summarized incidence rates of B-lymphoid neoplasms around the world

From: Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence

Population*

Representative CMV (%) seropositivity

B-neoplasms

(merged rates yr−1/105)**

p-value†

Refs

The US

44

44.72

N/A

Chihara et al. [55]

SEER Program [56]

US-born Asians

75

18.6

 < 0.05

Clarke et al. [52]

Li et al. [53]

Europe

70

25.44

 < 0.05

Zuhair et al. [36]

Middle East

(Iraq, Jordan, S. Arabia)

90

9.12

 < 0.05

Yaqo et al. [57]

Sub-Saharan Africa

 ~ 92

7.2

 < 0.05

Tomoka et al. [81]

Hong Kong

 > 90

11.49

 < 0.05

Bassig et al. [58]

East Asia (China, Japan)

 ~ 90

8.72

 < 0.05

Chihara et al. [55]

  1. *Males and females were combined. Worldwide population means of CMV seroprevalence by the International Agency for Research on Cancer (IARC) [35] were relied on in comparisons with annual rates of B-cell maladies. We made use of standardized population-based cancer registry records in Chihara et al.[55]
  2. **The crude numbers of extracted incidence rates of B-cell neoplasms were merged together in the middle column). Compounded incidences were preferred as a proviso for each world zone. Thus, rough rates depart from factual ones and should be taken as broadly consultative. Also, racial groups were collected under different protocols, excepting the Surveillance, Epidemiology, and End Results (SEER) 13 Incidence Database. Withal, unequal pathological categorization according to diagnosis (or cellular origin) and sub-classification criteria for B-cell leukemia/lymphoma in particular, varied from country to country introducing further biases. This hampered estimation of summated incidence rates. Consequently, workout of regional rates of B-cell neoplasms do not sum-up to estimates reported in the literature used
  3. †P-values were two-sided using the t-test. They reflect coupling strength between CMV seropositivity and incidence rate of B-cell neoplasms in the US versus other countries
  4. Age-adjusted incidence rates refer to patients > 70 years of age. This age group had the longest exposure to CMV and could not be strictly compared to global SEER data
  5. Remark: The differences in study populations, high false discovery rates and dissimilar calendar periods of observation in the reports used affected the calculations. These should be viewed with caution
Back to article page

Virology Journal

ISSN: 1743-422X